azasetron has been researched along with Emesis in 17 studies
azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the efficacy of olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) and improving the quality of life (QoL) of patients with cancer during chemotherapy." | 9.20 | QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. ( Chen, J; Li, H; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D; Zhang, H, 2015) |
| "Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration." | 9.14 | Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan." | 9.08 | [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 9.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma." | 9.08 | [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998) |
| "This study evaluated the efficacy of olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) and improving the quality of life (QoL) of patients with cancer during chemotherapy." | 5.20 | QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. ( Chen, J; Li, H; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D; Zhang, H, 2015) |
| "Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration." | 5.14 | Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. ( Chen, J; Liu, J; Liu, X; Tan, L; Yan, Z; Yang, H; Zhang, D, 2009) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs and is widely used in the clinical setting in Japan." | 5.08 | [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. ( Akiyama, M; Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 5.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "We performed a clinical evaluation on the antiemetic profile and the plasma concentration of Azasetron Hydrochloride (a new selective 5-HT3 receptor antagonist), in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma." | 5.08 | [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma]. ( Beppu, T; Doi, K; Egami, H; Kudo, S; Kuramoto, M; Masuda, Y; Matsuda, T; Ogawa, M; Ohara, C; Yamanaka, T, 1998) |
| " We theoretically evaluated the antiemetic effects of three 5-HT(3) receptor antagonists (granisetron, azasetron, palonosetron) on cisplatin-induced nausea and vomiting by estimating the time course of the 5-HT(3) receptor occupancy of serotonin." | 3.81 | Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin. ( Iwase, O; Nakajima, A; Nakamura, H; Okuyama, K; Takayanagi, R; Yamada, Y; Yokoyama, H; Yoshimoto, K, 2015) |
| "RESULTS In 37 women with ovarian cancer, three symptoms, nausea, appetite loss, and dietary intake, were significantly improved by primarily adding aprepitant to double combination therapy in the delayed phase of MEC." | 2.84 | Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. ( Abiko, K; Baba, T; Hamanishi, J; Imai, S; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yamanoi, K; Yoshioka, Y, 2017) |
| " We analyzed 5-HT3 receptor occupancy of serotonin by integrating pharmacokinetic and receptor-binding kinetic parameters based on the receptor occupancy theory to compare the strength of the antiemetic effects of three dosage regimens of azasetron hydrochloride." | 1.34 | [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin]. ( Fujita, M; Iga, T; Okuyama, K; Ozeki, T; Takayanagi, R; Yamada, Y; Yokoyama, H, 2007) |
| "Azasetron was found to improve the increased frequency of defecation, but exerted no obvious effect on hypophagia or on the decreased frequency of drinking." | 1.31 | [Delayed emesis induced by the chemotherapeutic agent doxorubicin hydrochloride in dogs]. ( Haga, K; Hashimoto, T; Inaba, K; Syoji, H, 2000) |
| "Azasetron has a high affinity for 5-HT3 receptor in the gastrointestinal organ, the very site of its antiemetic action against chemotherapy-induced emesis." | 1.30 | High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats. ( Asano, K; Fukuda, T; Haga, K; Katayama, K, 1997) |
| "Domperidone did not inhibit these cytotoxic agents-induced emeses." | 1.29 | The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. ( Fukuda, T; Haga, K; Inaba, K; Morimoto, Y; Setoguchi, M; Shoji, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, H | 1 |
| Yokoyama, H | 3 |
| Takayanagi, R | 3 |
| Yoshimoto, K | 3 |
| Nakajima, A | 1 |
| Okuyama, K | 4 |
| Iwase, O | 2 |
| Yamada, Y | 4 |
| Liu, J | 2 |
| Tan, L | 2 |
| Zhang, H | 1 |
| Li, H | 1 |
| Liu, X | 2 |
| Yan, Z | 2 |
| Chen, J | 2 |
| Yang, H | 2 |
| Zhang, D | 2 |
| Hashizume, J | 1 |
| Higuchi, N | 1 |
| Sato, K | 1 |
| Kodama, Y | 1 |
| Matsunaga, N | 1 |
| Sakamoto, T | 1 |
| Yamaguchi, K | 2 |
| Nakamura, T | 1 |
| Kitahara, T | 1 |
| Sasaki, H | 1 |
| Koshiyama, M | 1 |
| Matsumura, N | 1 |
| Imai, S | 1 |
| Yamanoi, K | 1 |
| Abiko, K | 1 |
| Yoshioka, Y | 1 |
| Hamanishi, J | 1 |
| Baba, T | 1 |
| Konishi, I | 1 |
| Ayuhara, H | 1 |
| Ozeki, T | 3 |
| Fujita, M | 1 |
| Iga, T | 1 |
| Tsukuda, M | 1 |
| Mochimatsu, I | 1 |
| Furukawa, M | 1 |
| Kohno, H | 1 |
| Kawai, S | 1 |
| Enomoto, H | 1 |
| Yago, T | 1 |
| Matsuda, H | 1 |
| Ikema, Y | 1 |
| Zhou, L | 1 |
| Haga, K | 3 |
| Inaba, K | 3 |
| Shoji, H | 2 |
| Morimoto, Y | 1 |
| Fukuda, T | 3 |
| Setoguchi, M | 2 |
| Kimura, E | 2 |
| Niimi, S | 2 |
| Watanabe, A | 2 |
| Akiyama, M | 1 |
| Tanaka, T | 2 |
| Katayama, K | 1 |
| Asano, K | 1 |
| Beppu, T | 1 |
| Ogawa, M | 1 |
| Yamanaka, T | 1 |
| Egami, H | 1 |
| Ohara, C | 1 |
| Masuda, Y | 1 |
| Kudo, S | 1 |
| Kuramoto, M | 1 |
| Doi, K | 1 |
| Matsuda, T | 1 |
| Ozaki, A | 1 |
| Sukamoto, T | 1 |
| Syoji, H | 1 |
| Hashimoto, T | 1 |
| Tahara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting[NCT02970643] | 48 participants (Anticipated) | Interventional | 2016-07-31 | Enrolling by invitation | |||
| Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent Nausea and Vomiting Induced by Chemotherapy：:A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial[NCT05805800] | Phase 3 | 238 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911] | Phase 3 | 120 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 15 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 17 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Aprepitant Regimen | 15 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）" (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 18 |
| Control Regimen | 15 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 7 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 6 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 41 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 35 |
| Control Regimen | 40 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 31 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 30 |
7 trials available for azasetron and Emesis
| Article | Year |
|---|---|
QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compou | 2015 |
Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bridged Bicyclo Comp | 2017 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heteroc | 2009 |
[A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
Topics: Aged; Antiemetics; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Female; Granisetron; Head and | 1995 |
[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; | 1996 |
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug | 1997 |
[Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma].
Topics: Aged; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepato | 1998 |
10 other studies available for azasetron and Emesis
| Article | Year |
|---|---|
Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Constipation; Creatinine; | 2015 |
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Comp | 2016 |
Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compoun | 2009 |
[Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
Topics: Antiemetics; Antineoplastic Agents; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; C | 2007 |
[Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimi | 2008 |
The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
Topics: Administration, Oral; Animals; Antiemetics; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, He | 1993 |
High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats.
Topics: Animals; Antiemetics; Binding Sites; Bridged Bicyclo Compounds, Heterocyclic; Granisetron; Intestine | 1997 |
Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist.
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic | 1999 |
[Delayed emesis induced by the chemotherapeutic agent doxorubicin hydrochloride in dogs].
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Defecation; Disease Models, | 2000 |
The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist.
Topics: Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds; Bri | 1991 |